

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	Att'y Ref: A28-011	Serial No: 10/728,246
	Applicant: ORSER et al.	
	Filing Date: Dec. 4, 2003	Art Unit:

United States Patent Documents						
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
/KM/	US 2001/ 001061 A1	2001-05- 10	SAFAR JIRI G et al.			

Foreign Patent Documents							
Examiner Initial	Publication Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
/KM/	WO 01 07473 A	2001-02- 01	WIPO				
/KM/	WO 01 14412 A	2001-03- 01	WIPO				

Examiner: /Keri Moss/	Date Considered: 04/02/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.	



Examiner Initial	Other Documents (by Title, Author Date, Pertinent Pages, Etc.)
/KM/	Chitnumsub et al. (1999) "The Nucleation of Monomeric Parallel Beta-Sheet-Like Structures and Their Self-Assembly in Aqueous Solution" <i>Biorganic &amp; Medicinal Chemistry</i> 7 (1): 39-59.
/KM/	Fraser et al. (1994) "Conformation and Fibrillogenesis of Alzheimer A-beta Peptides with Selected Substitution of Charged Residues" <i>Journal of Molecular Biology</i> 244 (1): 64-73.
/KM/	Wilson et al. (2000) "Conformational Transitions in Model Silk Peptides" <i>Biophysical Journal</i> 78 (5): 2690-2701.

Examiner: /Keri Moss/	Date Considered: 04/02/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.	



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	Att'y Ref: A28-011	Serial No: 10/728,246
	Applicant: ORSER et al.	
	Filing Date: Dec. 4, 2003	Art Unit:

United States Patent Documents						
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
/KM/	US 2002/0042121	2002-04-11	RIESNER et al.			

Foreign Patent Documents							
Examiner Initial	Publication Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

Examiner Initial	Other Documents (by Title, Author Date, Pertinent Pages, Etc.)
------------------	--

Examiner: /Keri Moss/	Date Considered: 04/02/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.	

**INFORMATION DISCLOSURE CITATION**



Atty. Docket No.: ADL-101	Application No.: 10/728,246
Applicant: Cindy ORSER et al.	
Filing Date: 4 December 2003	Group Art Unit: Not Yet Assigned

**U.S. PATENT DOCUMENTS**

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
/KM/	6,750,025	06/2004	Hammond et al.			
/KM/	6,677,125	01/2004	Prusiner et al.			
/KM/	6,214,565	04/2001	Prusiner et al.			
/KM/	2003/0215880	11/2003	Burton et al.			

**FOREIGN PATENT DOCUMENTS**


/KM/	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
/KM/	WO 2004/018511	03/2004	PCT			
/KM/	WO 03/085086	10/2003	PCT			
/KM/	WO 00/43791	07/2000	PCT			
/KM/	WO 00/02575	01/2000	PCT			
/KM/	WO 97/43649	11/1997	PCT			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

/KM/	Shaked, GM et al., "A Protease-resistant Prion Protein Isoform Is Present in Urine of Animals and Humans Affected with Prion Disease", <i>J.B.C.</i> 276(34):31479-31482, August 24, 2001.
/KM/	Pan, K-M et al., "Conversion of $\alpha$ -helices into $\beta$ -sheets features in the formation of the scrapie prion proteins", <i>Proc. Natl. Acad. Sci. USA</i> 90:10962-10966, December 1993.

Examiner      /Keri Moss/	Date Considered      04/02/2007
---------------------------	---------------------------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## INFORMATION DISCLOSURE CITATION

Atty. Docket No.: ADL-101				Application No.: 10/728,246			
Applicant: Cindy ORSER et al.							
Filing Date: 4 December 2003				Group Art Unit: Not Yet Assigned			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
/KM/	B1	Anantharamaiah, G.M., et al., "Studies of Synthetic Peptide Analogs of the Amphipathic Helix", <i>J. Biol. Chem.</i> 260(18):10248-10255, 1985.					
/KM/	B2	Anfinsen, C.B., "Principles that Govern the Folding of Protein Chains", <i>Science</i> 181(4096):223-230, 1973.					
/KM/	A1	Baba, M., et al., "Aggregation of $\alpha$ -Synuclein in Lewy Bodies of Sporadic Parkinson's Disease and Dementia with Lewy Bodies", <i>Am. J. Pathology</i> 152(4):879-885, 1998.					
/KM/	B3	Baker, D., "A surprising simplicity to protein folding", <i>Nature</i> 405:39-42, 2000.					
/KM/	A2	Booth, D.R., et al., "Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis", <i>Nature</i> 385:787-793, 1997.					
/KM/	A3	Carrell, R.W. et al., "Conformational Disease", <i>The Lancet</i> 350:134-138, 1997.					
/KM/	B4	Chiti, F., et al., "Designing conditions for <i>in vitro</i> formation of amyloid protofilaments and fibrils", <i>Proc. Natl. Acad. Sci. USA</i> 96:3590-3594, 1999.					
/KM/	B5	Daura, X., et al., "Reversible Peptide Folding in Solution by Molecular Dynamics Simulation", <i>J. Mol. Biol.</i> 280:925-932, 1998.					
/KM/	A4	Dobson, C.M., "Protein misfolding, evolution and disease", <i>TIBS</i> 24:329-332, 1999.					
Examiner /Keri Moss/				Date Considered 04/02/2007			
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							



## INFORMATION DISCLOSURE CITATION


Atty. Docket No.: ADL-101				Application No.: 10/728,246			
Applicant: Cindy ORSER et al.							
Filing Date: 4 December 2003				Group Art Unit: Not Yet Assigned			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
/KM/	A5	Dobson, C.M., "The structural basis of protein folding and its links with human disease", <i>Phil. Trans. R. Soc. London B</i> 356:133-145, 2001.					
/KM/	B6	Dobson, C.M. et al., "Kinetic studies of protein folding using NMR spectroscopy", <i>Nature Structural Biology Suppl</i> :504-507, July 1998.					
/KM/	A6	Epstein, F.H., "Molecular Basis Of The Neurodegenerative Disorders", <i>New. Eng. J. Med.</i> 340(25):1970-1980, 1999.					
/KM/	B7	Isenman, D.E., et al., "The Structure and Function of Immunoglobulin Domains", <i>Proc. Natl. Acad. Sci. USA</i> 72(2):548-552, 1975.					
/KM/	B8	Krawczak, M., et al., "Human Gene Mutation Database - A Biomedical Information and Research Resource", <i>Human Mutation</i> 15:45-51, 2000.					
/KM/	A7	Lansbury, P.T., "Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease", <i>Proc. Natl. Acad. Sci. USA</i> 96:3342-3344, 1999.					
/KM/	B9	Levy, E., et al., "Stroke In Icelandic Patients With Hereditary Amyloid Angiopathy Is Related To A Mutation In The Cystatin C Gene, An Inhibitor Of Cysteine Proteases", <i>J. Exp. Med.</i> 169:1771-1778, 1989.					
/KM/	A8	Liao, Y-C.J., et al., "Human Prion Protein cDNA: Molecular Cloning, Chromosomal Mapping, and Biological Implications", <i>Science</i> 233:364-367, 1986.					
Examiner /Keri Moss/				Date Considered 04/02/2007			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



## INFORMATION DISCLOSURE CITATION

Atty. Docket No.: ADL-101		Application No.: 10/728,246					
Applicant: Cindy ORSER et al.		OCT 28 2005					
Filing Date: 4 December 2003		Group Art Unit: Not Yet Assigned					
U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/KM/	A9	MacPhee, C.E., et al., "Chemical Dissection and Reassembly of Amyloid Fibrils Formed by a Peptide Fragment of Transthyretin", <i>J. Mol. Biol.</i> 297:1203-1215, 2000.					
/KM/	B10	Matouschek, A., et al., "Mapping the transition state and pathway of protein folding by protein engineering", <i>Nature</i> 340:122-126, 1989.					
/KM/	A10	Nguyen, J., et al., "Prion Protein Peptides Induce $\alpha$ -Helix to $\beta$ -Sheet Conformational Transitions", <i>Biochemistry</i> 34:4186-4192, 1995.					
/KM/	A11	Oesch, B., et al., "A Cellular Gene Encodes Scrapie PrP 27-30 Protein", <i>Cell</i> 40:735-746, 1985.					
/KM/	A12	Perutz, M.F., "Glutamine repeats and neurodegenerative disease: molecular aspects", <i>TIBS</i> 24:58-63, 1999.					
/KM/	A13	Prusiner, S.B., et al., "Prion Protein Biology", <i>Cell</i> 93:337-348, 1998.					
/KM/	A14	Riordan, J.R., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA", <i>Science</i> 245:1066-1073, 1989.					
/KM/	A15	Salmona, M., et al., "Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126", <i>Biochemical Journal</i> 342:207-214, 1999.					
/KM/	A16	Schatzl, H.M., "Prion Protein Gene Variation Among Primates", <i>J. Mol. Biol.</i> 245:362-374, 1995.					
Examiner /Keri Moss/				Date Considered 04/02/2007			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

# INFORMATION DISCLOSURE CITATION

Atty. Docket No.: ADL-101				Application No.: 10/728,246			
Applicant: Cindy ORSER et al.							
Filing Date: 4 December 2003				Group Art Unit: Not Yet Assigned			
 <b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>							
	Document Number	Date	Country	Class	Sub Class	Translation Yes or No	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
/KM/	A17	Soto, C., "Protein misfolding and disease; protein refolding and therapy", <i>FEBS Letters</i> 498:204-207, 2001.					
/KM/	B11	Speed, M.A., et al., "Polymerization Mechanism of Polypeptide Chain Aggregation", <i>Biotechnology and Bioengineering</i> 54(4):333-343, 1997.					
/KM/	B12	Speed, M.A., et al., "Specific aggregation of partially folded polypeptide chains: The molecular basis of inclusion body composition", <i>Nature Biotechnology</i> 14:1283-1287, 1996.					
/KM/	A18	Spillantini, M.G., "α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies", <i>Proc. Natl. Acad. Sci. USA</i> 95:6469-6473, 1998.					
/KM/	A19	Spillantini, M.G., "α-Synuclein in Lewy bodies" <i>Nature</i> 388:839-840, 1997.					
/KM/	A20	Stahl, N., et al., "Prions and prion proteins", <i>The FASEB Journal</i> 5:2799-2807, 1991.					
/KM/	B13	Surewicz, W.K., et al., "Infrared spectroscopic evidence of conformational transitions of an atrial natriuretic peptide", <i>Proc. Natl. Acad. Sci. USA</i> 84:7028-7030, 1987.					
/KM/	A21	Thomas, P.J., et al., "Defective protein folding as a basis of human disease", <i>TIBS</i> 20:456-459, 1995.					
/KM/	A22	Westaway, D., et al., "Distinct Prion Proteins in Short and Long Scrapie Incubation Period Mice", <i>Cell</i> 51:651-662, 1987.					
/KM/	A23	Prior, R., et al., "Selective binding of Soluble Aβ1-40 and Aβ1-42 to a Subset of Senile Plaques", <i>Am. J. Pathology</i> 148(6):1740-1756, 1996.					
Examiner /Keri Moss/				Date Considered 04/02/2007			
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

number. Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> Date Submitted: January 3, 2007 (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/728246
		Filing Date	12/4/2003
		First Named Inventor	Cindy Orser
		Art Unit	1743
		Examiner Name	Unassigned
		Attorney Docket Number	070538-0115

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code* Number* Kind Code <sup>3</sup> (If known)				
/KM/		WO 01/50134 A2	07/12/2001	Krishnamurthy		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>

Examiner Signature	/Keri Moss/	Date Considered	04/02/2007
-----------------------	-------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**